Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY™ (maribavir, TAK-620) in post-transplant refractory† CMV infections with or without resistance‡ (R/R) were published in the journal of Clinical Infectious Diseases (CID).

Related Keywords

Osaka ,Japan ,United States ,America ,Clin Virol ,Takeda Pharmaceuticals United States Inc ,International Report On Organ Donation ,Takeda Pharmaceutical Company Limited ,World Health Organization ,Takeda Pharmaceutical Company ,Exchange Commission ,Springer International Publishing ,Infectious Diseases Society Of America ,The Global Phase ,Now Published In Clinical Infectious Diseases ,Show For The Primary Endpoint ,Key Secondary Endpoint ,Lower Limit Of Quantification ,Symptom Control ,Maintenance Through Week ,Pharmaceutical Company Limited ,Clinical Infectious Diseases ,Infectious Diseases Society ,Reduced Antiviral Activity When Co Administered ,Failure During Treatment ,Adverse Reactions ,Virologic Response Due ,Full Prescribing ,Rare Genetics ,Plasma Derived Therapies ,Annual Report ,Refractory Cytomegalovirus Infections With ,Without Resistance Post Transplant ,Results From ,Clin Infect ,Internal Communication ,Pharmaceuticals United States Inc All ,International Report ,Organ Donation ,Current Scientific Evidence ,Hematopoietic Cell ,Leed G ,Cytomegalovirus Infections ,Hematopoietic Stem Cell Transplantation ,Current Status ,Intj Mol ,Solid Organ Transplant ,European Blood ,Marrow Transplantation Textbook ,Refractory Cytomegalovirus Infection ,Transplant Recipients ,Hematopoietic Stem Cell Transplant ,Biol Blood Marrow ,Media Contact ,Takeda ,Harmaceutical ,Ivotal Phase 3 Solstice Clinical Trial ,Ivtencity ,Maribavir ,Ak 620 ,Obi Umeh ,Fernanda Silveira ,Anciclovir ,Alganciclovir ,Idofovir ,Oscarnet ,Cytomegalovirus ,Dmv ,Eta Herpesvirus ,Olstice ,Virologic Failure ,Rug Concentrations ,Ncology ,Care Genetics ,Hematology ,Neuroscience ,Astroenterology ,